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Introduction: In the adult human breast, hyperplastic enlarged lobular unit (HELU) and atypical ductal hyperplasia
(ADH) are two common abnormalities that frequently coexist with ductal carcinoma in situ (DCIS). For this reason,
they have been proposed as the early steps in a biological continuum toward breast cancer.
Methods: We investigated in silico the expression of 369 genes experimentally recognized as involved in
establishing and maintaining epithelial cell identity and mammary gland remodeling, in HELUs or ADHs with
respect to the corresponding patient-matched normal tissue.
Results: Despite the common luminal origin, HELUs and ADHs proved to be characterized by distinct gene profiles
that overlap for 5 genes only. While HELUs were associated with the overexpression of progesterone receptor (PGR),
ADHs were characterized by the overexpression of estrogen receptor 1 (ESR1) coupled with the overexpression of
some proliferation-associated genes.
Conclusions: This unexpected finding contradicts the notion that in differentiated luminal cells the expression of
estrogen receptor (ER) is dissociated from cell proliferation and suggests that the establishing of an ER-dependent
signaling is able to sustain cell proliferation in an autocrine manner as an early event in tumor initiation. Although
clinical evidence indicates that only a fraction of HELUs and ADHs evolve to invasive cancer, present findings warn
that exposure to synthetic progestins, frequently administered as hormone-replacement therapy, and estrogens,
when abnormally produced by adipose cells and persistently present in the stroma surrounding the mammary
gland, may cause these hyperplastic lesions.
Keywords: Mammary epithelial cell identity, Hyperplastic enlarged lobular unit, Atypical ductal hyperplasia, Ductal
carcinoma in situBackground
According to the model proposed for breast cancer pro-
gression, normal epithelial cells progressively accumulate
molecular alterations that result in a series of histologi-
cally identifiable, even if non-obligate, cancer precursors.
Among the precursors earliest in the progression is hy-
perplastic enlarged lobular unit (HELU), a common ab-
normality in the adult female human breast [1]. HELU
consists of an abnormal enlargement (often up to 100-
fold) of normal terminal duct lobular unit (TDLU) from
which it evolves. Histologically, the epithelial cells that
line these dilated lobules appear increased in number* Correspondence: danila.coradini@gmail.com
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unless otherwise stated.and changed in morphology with the transformation of
low cuboidal epithelium to irregular tall columnar epithe-
lium. The transformation may be associated with aty-
pia, which is characterized by the presence of round to
ovoid nuclei not perpendicularly oriented to the base-
ment membrane, and an increased ratio of nuclear to
cytoplasmic [2].
Observational studies have indicated that HELU fre-
quently coexists with more complex proliferative lesions
such as atypical ductal hyperplasia (ADH) and low-grade
ductal carcinoma in situ (DCIS) [3], suggesting it occurs
as the first step in the biological continuum toward
breast cancer [4]. For this reason, the presence of HELU
has been proposed as a potential valuable risk factor to
be thoroughly investigated and monitored [5], though
clinical evidence has indicated that only a small fraction
of HELUs actually progress to invasive breast cancer [6].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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formation of a mammary epithelial cell, there are per-
turbations in cell type identity. This term refers to the
predetermined, tissue-specific set of genes that charac-
terizes every cell within a multicellular organism. These
genes are conserved during DNA replication and mitosis
so that daughter cells retain the differentiated cell type of
the parental cell (cell memory). Preservation of cell iden-
tity depends on a class of proteins that are collectively
termed maintenance proteins [7]. Studies have shown that
maintenance proteins, among which Trithorax- and
Polycomb-group proteins are the best characterized, act
in a somatically heritable but DNA-independent man-
ner (i.e., epigenetically) and regulate gene expression
through DNA methylation, histone modification, and
chromatin remodeling [8,9]. Because of their recognized
role in the control of cell identity and mammary gland
remodeling, perturbations in maintenance protein ex-
pression can affect cell identity and trigger neoplastic
transformation [10].
Here we used publicly accessible microarray datasets
to compare, in a series of HELUs from noncancerous
adult breasts and corresponding patient-matched, normal
TDLUs, the expression pattern of genes experimentally
recognized to be involved in regulating cell identity and
mammary gland remodeling. Furthermore, in agreement
with the hypothesis that HELU may represent the bio-
logical precursor of ADH to be used for the early assess-
ment of breast cancer risk, we compared the gene
expression profile of HELU with that of a series of puta-
tive invasive breast cancer precursors, namely ADH and
DCIS, and corresponding patient-matched, histologically
normal tissue.
Methods
Tissue samples
As described in the original article by Lee et al. [11],
well-developed, single-layer type HELUs with minimal
nuclear atypia and paired normal TDLUs were derived
from 8 women's noncancerous breast tissues. In each
formalin-fixed, paraffin-embedded tissue biopsy, HELUs
and TDLUs were isolated by laser capture microdissec-
tion. Gene expression was determined using U133-X3P
Human GeneChip oligo-based microarray (Affymetrix,
Santa Clara, CA, USA) and the corresponding micro-
array dataset was publicly available at the ArrayExpress
web site (http://ebi.ac.uk/arrayexpress/) under accession
number E-GEOD-7377.
To compare the gene expression profile of HELUs with
that of ADHs and DCISs, we used another publicly
accessible dataset containing microarray data from coex-
isting patient-matched samples of ADH and DCIS lesions
and corresponding histologically normal tissue, isolated by
laser capture microdissection from surgical specimens ofuntreated patients with estrogen receptor (ER)-positive
(immunohistochemically evaluated) sporadic breast cancer
[12]. Gene expression was determined using HG-U133A
Human GeneChip microarray (Affymetrix) and the corre-
sponding microarray dataset was available at the ArrayEx-
press web site under accession number E-GEOD-16873.
Gene set selection
After an extensive literature review, we established a
panel of 369 genes that included genes associated with
establishing and maintaining cell identity and with mam-
mary gland remodeling, or that were involved in cell fate
decision, cell growth control, cell polarity and adhesion,
and steroid and transforming growth factor β (TGF-β)
signaling. Of these 369 genes, 8 had no corresponding
probe sets on the U133-X3P GeneChip and 40 had no
corresponding probe sets on the HG-U133A GeneChip.
Therefore, for the E-GEOD-7377 dataset, the gene set
was actually composed of 361 elements for 842 Affyme-
trix probe sets, whereas for the E-GEOD-16873 dataset,
the gene set was actually composed of 329 elements for
639 Affymetrix probe sets. A total of 326 genes were
present in both datasets. GeneAnnot system v2.2 (http://
bioinfo2.weizmann.ac.il/geneannot/) provided informa-
tion about the quality of connection between each probe
set and the corresponding gene in terms of sensitivity
and specificity [13]. Specifically, the sensitivity, defined
as the fraction of probes in a probe set that match a re-
spective gene, is the number of matching probes in a
given probe set divided by the total number of probes in
this probe set. The specificity indicates to what extent
the probes of a probe set bind to genes, and it sums the
number of probes that match a given gene (assigning
lower weight to probes that match additional genes)
divided by the total number of probes that match add-
itional genes in a specific manner.
Statistical analysis
Because some genes are recognized by more than a single
probe set, each of which is characterized by an individual
specificity and sensitivity that uniquely contribute to the
gene expression value, a mean gene expression value was
calculated after weighting each probe set for its own sensi-
tivity and specificity, prior to the analysis. Namely, each
expression value was multiplied by the semi sum of the
sensitivity and specificity of the corresponding probe set.
The differential gene expression between HELUs and
TDLUs and among histologically normal tissue, ADHs,
and DCISs was evaluated using analysis of variance after
correction for multiple testing. To correct for multiple
testing, the false discovery rate (FDR) with a cut-off of 0.1
was used [14]. All analyses were performed using the open
source software R 2.11.1 packages High Dimensional
Molecular Data (HDMD; http://www.R-project.org).
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Genes differentially expressed in HELUs
Compared with normal TDLUs, HELUs showed differen-
tial expression of only 28 genes (FDR < 0.1), the majority
of which were underexpressed. As shown in Figure 1, the
subset included genes encoding proteins typically involved
in cell fate decision (ABCG2, JAG2, MYC, NOTCH3,
PROM1, SOX9, and SOX10), embryonic development
(HOXB2, HOXC10, and HOXC11), cell differentiation
(ELF5, FOXA1, and PGR), epigenetic control of gene
transcription (EZH1, MLL4, and SMARCA4), and cell
adhesion (CDC42, CLDN10, EPCAM, ITGA6, ITGB, and
ITGB4). In addition, the subset included some genes
involved in the TGF-β signaling pathway (FOXC1 and
TGFB2) or encoding for growth factors (EGF, MFGE8,
and TGFA) or a cytokine receptor (IL7R).Genes differentially expressed in ADHs and DCISs
With respect to histologically normal tissue, ADHs and
DCISs were associated, respectively, with 28 and 41 differ-
entially express genes (FDR < 0.1), as shown in Figure 2.
Notably, all genes differentially expressed in ADHs were
also differentially expressed (in a similar manner) in
DCISs, corroborating the hypothesis that ADH is the
biological precursor of DCIS.Figure 1 Forest plot of the genes differentially expressed between hy
normal terminal duct lobular units (TDLUs) with a false discovery rate
change ± 95% confidence interval (CI).Most of the genes in common between ADHs and DCISs
encoded proteins involved in cell fate decision (JAG2
and SOX10), embryonic development (HOXA4, HOXA5,
HOXA7, HOXA9, and HOXB6), cell differentiation (ELF5
and GATA3) and organization (ACTA2, CD24, CLDN7,
JAM2, JAM3, KRT17, MME, and TPJ3), and epigenetic con-
trol of gene transcription (CBX8 and EZH2). The set also
included genes involved in the canonical and non-canonical
TGF-β signaling pathways (AKT1, FOXC1, ID2, SNAI2,
TGFBR3, and WNT5B) or encoding for growth factors
(EGF and PDGFA) or a growth factor receptor (EGFR). An
additional 13 genes were specifically associated with DCISs.
The set included ACTL6A that encodes a Trithorax protein
(Baf53A) with regulatory activity in several ATP-dependent
chromatin-remodeling complexes, 2 members of the clau-
din adhesion molecule family (CLDN5 and CLDN8), 1 epi-
thelial cell adhesion molecule (EPCAM), 2 basal phenotype-
associated keratins (KRT5 and KRT14), 1 ER (ESR1), 2
cyclins involved in the G2/M-phase transition of cell cycle
(CCNB1 and CCNB2), 1 cell proliferation-associated antigen
(MKI67), 1 chemokine (CXCL12), 1 growth factor (MFGE8),
and 1 growth factor receptor (FGFR3).
Genes differentially expressed in HELUs and ADHs/DCISs
To assess the hypothesis that HELU is the putative bio-
logical precursor of ADHs and DCISs, we compared theperplastic enlarged lobular units (HELUs) and corresponding
(FDR) < 0.1. For each gene, the change is expressed as fold
Figure 2 Forest plot of the genes differentially expressed between atypical ductal hyperplasia (ADH) (upper panel) or ductal carcinoma in
situ (DCIS) (lower panel) and histologically normal (HN) tissue with a FDR <0.1. For each gene, the change is expressed as fold change ± 95% CI.
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that of genes differentially expressed in ADHs/DCISs.
As shown in Table 1, HELUs and ADHs/DCISs shared
a very small subset of genes, which included EGF, ELF5,
FOXC1, JAG2, and SOX10, all underexpressed with
respect to the corresponding normal tissue.
Discussion
Overall, the pattern of gene expression in HELUs was
consistent with the lobuloalveolar phenotype that char-
acterizes this lesion. In fact, HELUs demonstrated the
marked underexpression of genes typically related to the
maintenance of a stem-like state, and the concomitant
overexpression of genes specifically involved in forming
the lobuloalveolar structure. Indeed, genes notably
underexpressed in HELUs include ABCG2 and PROM1,
which code for 2 stemness-associated markers [15,16],
and NOTCH3 and JAG2, which encode Notch receptor
3 and Notch receptor ligand Jagged 2, respectively, 2
elements of the Notch signaling pathway that play a
pivotal role in promoting a stem-like state in tumors
with a basal phenotype [17,18]. Notably, concomitant
underexpression of MYC corroborates the direct rela-
tionship between the JAG2-Notch receptor signaling
pathway and c-Myc activity. The Notch signaling, in fact,
promotes cell survival by regulating the expression of
c-Myc transcription factor [19], which in turn, regulates
the expression of JAG2 [20] according to a feed-forward-loop transcriptional network. Other genes also
underexpressed in HELUs include SOX9 and SOX10,
which encode two members of the sex-determining
region Y-related (SOX) gene family of transcription
factors. The proteins these genes encode are involved,
as part of a highly coordinated transcriptional program,
in maintaining the stem-like state and in activating the
epithelial-to-mesenchymal transition [21,22]. Specifically
expressed in myoepithelial cells and breast basal-like
carcinomas [23], SOX9 and SOX10 have proven to be
negatively associated with FOXA1, which encodes FoxA1
transcription factor, an essential regulator of mammary
ductal morphogenesis [24]. Consistent with this evidence,
we found that underexpression of SOX9 and SOX10 was
associated with FOXA1 overexpression in HELUs. In
contrast with SOX9 and SOX10 underexpression, SOX4,
another member of SOX gene family that plays a role in
commitment to the differentiated luminal phenotype and
to be progesterone-regulated [25], was constitutively
expressed in HELUs.
In keeping with the physiologic role of progesterone in
mammary gland branching morphogenesis [26], a key
gene overexpressed in HELUs was PGR, which encodes
progesterone receptor, the nuclear ligand-activated recep-
tor required for the canonical genomic mechanism of
action of progesterone. Notably, in addition to proges-
terone receptor, HELUs constitutively expressed PGRMC1
and PGRMC2, which encode progesterone receptor
Table 1 Genes differentially expressed in HELUs versus TDLUs and ADH/DCIS versus HN tissue with a FDR < 0.1
Gene
symbol
Gene name HELUs vs. TDLUs ADH/DCIS vs. HN
Fold change
(95% CI)
FDR Fold change
(95% CI)
FDR
Common between HELUs and ADH/DCIS
EGF Epidermal growth factor −4.17 (ND, ND) 0.019 −1.04 (−1.71, −0.37) 0.034
ELF5 E-74-like factor 5 −2.46 (−3.60, −1.31) 0.058 −1.88 (−2.75, −1.00) 0.005
FOXC1 Forkhead box C1 −2.69 (−3.63, −1.76) 0.023 −0.95 (−1.38, −0.51) 0.004
JAG2 Jagged 2 −0.53 (−0.82, −0.23) 0.078 −0.92 (−1.37, −0.48) 0.006
SOX10 SRY (sex determining region Y)-box 10 −1.16 (−1.69, −0.64) 0.058 −1.38 (−1.92, −0.85) 0.001
Exclusive to HELUs
ABCG2 ATP-binding cassette, sub-family G, member 2 −2.84 (−4.28, −1.39) 0.073 −0.62 (−1.20, −0.04) 0.149
CDC42 Cell division cycle 42 0.66 (0.25, 1.07) 0.091 0.99 (−0.12, 0.31) 0.914
CLDN10 Claudin 10 −2.70 (−4.52, −1.06) 0.091 0.33 (−0.26, 0.93) 0.864
EPCAM Epithelial cell adhesion molecule 0.88 (0.60, 1.17) 0.019 0.14 (−0.42, 0.69) 0.928
EZH1 Enhancer of zeste homolog 1 −0.74 (−1.12, −0.35) 0.073 0.12 (−0.35, 0.58) 0.928
FOXA1 Forkhead box A1 2.03 (1.05, 3.00) 0.064 0.48 (−0.28, 1.25) 0.855
HOXB2 Homeobox B2 1.83 (1.40, 2.26) 0.008 −0.07 (−0.72, 0.58) 0.959
HOXC10 Homeobox C10 1.09 (ND, ND) 0.091 0.22 (−0.30, 0.74) 0.914
HOXC11 Homeobox C11 3.03 (1.22, 4.84) 0.091 0.13 (−0.15, 0.42) 0.913
IL7R Interleukin 7 receptor −2.33 (−3.75, −0.90) 0.091 0.23 (−0.38, 0.84) 0.914
ITGA6 Integrin, alpha 6 −0.85 (−1.28, −0.41) 0.073 −0.27 (−1.15, 0.60) 0.914
ITGB1 Integrin, beta 1 −0.82 (−1.17, −0.48) 0.049 0.58 (0.12, 1.04) 0.830
ITGB4 Integrin, beta 4 −0.81 (−1.23, −0.38) 0.073 −0.02 (−0.34, 0.30) 0.960
MFGE8 Milk fat globule-EGF factor 8 −1.19 (−1.87, −0.52) 0.078 −0.20 (−0.60, 0.20) 0.899
MLL4 Myeloid/lymphoid or mixed-lineage leukemia 4 −0.61 (−0.99, −0.22) 0.092 0.04 (−0.60, 0.68) 0.960
MYC v-Myc myelocytomatosis viral oncogene homolog (avian) −2.85 (−4.46, −1.24) 0.078 −0.45 (−1.19, 0.28) 0.855
NOTCH3 Notch homolog 3 −0.49 (−0.76, −0.23) 0.077 0.04 (−0.22, 0.30) 0.959
PGR Progesterone receptor 2.46 (1.49, 3.42) 0.038 0.13 (−1.21, 1.46) 0.959
PROM1 Prominin 1 −3.17 (−4.98, −1.36) 0.078 −0.78 (−1.96, 0.40) 0.849
SMARCA4 SWI/SNF-related, matrix-associated, actin-dependent
regulator of chromatin, subfamily a, member 4
−0.77 (−1.21, −0.34) 0.078 0.11 (−0.20, 0.42) 0.914
SOX9 SRY (sex determining region Y)-box 9 −2.45 (−3.58, −1.31) 0.058 −0.26 (−1.01, 0.49) 0.914
TGFA Transforming growth factor, alpha −1.50 (−2.41, −0.58) 0.091 −0.08 (−0.42, 0.25) 0.928
TGFB2 Transforming growth factor, beta 2 −1.04 (ND, ND) 0.092 −0.14 (−0.71, 0.42) 0.928
Exclusive for ADH/DCIS
ACTA2 Actin, alpha 2 −0.32 (−0.71, 0.06) 0.353 −2.25 (−2.95, −1.55) 0.0001
AKT1 v-Akt murine thymoma viral oncogene homolog 1 0.21 (−0.65, 1.08) 0.798 1.07 (0.41, 1.72) 0.029
CBX8 Chromobox homolog 8 −0.82 (−1.55, −0.08) 0.207 −0.97 (−1.58, −0.37) 0.029
CD24 CD24 molecule 0.29 (−0.89, 1.46) 0.799 0.65 (0.34, 0.95) 0.006
CLDN7 Claudin 7 0.24 (ND, ND) 0.789 0.49 (0.17, 0.82) 0.036
EGFR Epidermal growth factor receptor −0.65 (−1.20, −0.09) 0.184 −0.62 (−0.90, −0.34) 0.004
EZH2 Enhancer of zeste homolog 2 0.90 (−0.31, 2.12) 0.412 1.61 (0.87, 2.34) 0.004
GATA3 GATA-binding protein 3 1.12 (ND, ND) 0.136 0.95 (0.47, 1.43) 0.008
HOXA4 Homeobox A4 −1.13 (−1.92, −0.35) 0.123 −0.64 (−1.05, −0.22) 0.036
HOXA5 Homeobox A5 −1.40 (−2.61, −0.18) 0.189 −1.93 (−2.50, −1.35) 0.0001
HOXA7 Homeobox A7 −1.54 (−2.78, −0.29) 0.174 −0.77 (−1.14, −0.40) 0.006
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Table 1 Genes differentially expressed in HELUs versus TDLUs and ADH/DCIS versus HN tissue with a FDR < 0.1
(Continued)
HOXA9 Homeobox A9 NA NA −3.31 (−4.66, −0.96) 0.002
HOXB6 Homeobox B6 0.74 (ND, ND) 0.685 0.92 (0.32, 1.52) 0.075
ID2 Inhibitor of DNA-binding 2 −0.34 (−1.31, 0.64) 0.699 0.59 (0.21, 0.96) 0.063
JAM2 Junctional adhesion molecule 2 −0.62 (−2.06, 0.82) 0.638 −0.91 (−1.32, −0.49) 0.004
JAM3 Junctional adhesion molecule 3 −0.55 (−1.58, 0.49) 0.566 −1.09 (−1.50, −0.68) 0.001
KRT17 Keratin 17 0.06 (−0.65, 0.77) 0.948 −1.63 (−2.56, −0.71) 0.013
MME Membrane metallo-endopeptidase −0.44 (−1.35, 0.46) 0.611 −4.42 (−5.58, −3.25) <0.001
PDGFA Platelet-derived growth factor receptor, alpha polypeptide −0.98 (−1.77, −0.18) 0.174 −1.28 (−1.94, −0.63) 0.008
SNAI2 Snail homolog 2 −0.65 (−1.58, 0.29) 0.439 −1.79 (−2.59, −0.99) 0.004
TGFBR3 Transforming growth factor receptor, beta 3 −0.85 (−1.65, −0.05) 0.229 −2.02 (−3.09, −0.96) 0.010
TJP3 Tight junction protein 3 −0.47 (−0.99, 0.04) 0.294 1.13 (0.51, 1.76) 0.013
WNT5B Wingless-type MMTV integration site family, member 5B 0.21 (−0.86, 1.27) 0.864 −2.71 (−3.75, −1.66) 0.001
HELU, hyperplastic enlarged lobular unit; TDLU, terminal duct lobular unit; ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; HN, histologically
normal; FDR, false discovery rate; CI, confidence interval; vs., versus; ND, not determined; NA, probe set not available on HG-U133A Human GeneChip microarray.
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teins mediate the rapid transduction of the progesterone-
induced signaling through a non-genomic mechanism of
action [27]. Taken together, these findings support the
progesterone dependence of HELUs and explain the pecu-
liar hyperplastic aspect of this lesion.
Our results indicated that HOXB2, HOXC10, and
HOXC11 were overexpressed in HELUs. Interestingly, the
proteins these genes encode are involved in hormone-
dependent cell differentiation. HOXB2 is a downstream
target of retinoic acid, a well-known differentiation inducer
required to maintain the homeostasis of mammary gland
morphogenesis [28], and once activated, HOXB2 encodes a
transcription factor that negatively regulates growth in
breast cancer cells [29]. Similarly, HOXC10 and HOXC11
are transcriptionally regulated sex hormone steroids
[30,31], thus justifying their overexpression in HELUs.
By contrast, we surprisingly observed underexpression
of ELF5, which encodes ELF5, an epithelial-specific
transcription factor that plays a crucial role as lineage
gatekeeper during normal mammary development by
driving the formation of lobuloalveoli from luminal pro-
genitors [32,33]. Notably, we conducted another study of
the same genes investigated here, but in normal bipotent
progenitors, luminal precursors, and differentiated myoe-
pithelial and luminal differentiated cells [34]. Consistent
with the published role of ELF5, we found a positive asso-
ciation between ELF5 expression and luminal commit-
ment and differentiation as well as a negative association
between ELF5 expression and myoepithelial cells [34].
Hence, the unexpected underexpression of ELF5 that
we observed in HELUs suggests that silencing this gene,
possibly via promoter methylation, may be an early
event in pathologic transformation. Present results,
however, seem to indicate a mechanism of silencingdistinct from promoter methylation, as suggested by
the underexpression of pivotal genes that function as
transcriptional repressors in DNA methylation (EZH1)
[35], histone modification (MLL4) [36], or chromatin
remodeling (SMARCA4) [37]. A recent study provides
an intriguing alternative explanation, demonstrating that
progesterone drives mammary differentiation through the
receptor activator of necrosis factor kappa B (RANK)
ligand-mediated induction of ELF5 in luminal progenitor
cells [38]. In fact, in the absence of progesterone, the
luminal compartment is composed of mature sensor cells,
which express PGR but not ELF5, and mature secretory
cells, which express ELF5. After binding its receptor,
progesterone induces sensor cells to secrete RANK ligand,
the pivotal paracrine mediator of progesterone function
[39]. RANK ligand, through ELF expression, then induces
epithelial stem cell proliferation and forces asymmetric
expansion and differentiation toward the secretory cell
lineage of luminal progenitor cells. Present results fit this
model well and suggest that HELUs are mainly composed
of sensor cells characterized by the concomitant overex-
pression of PGR and underexpression of ELF5.
Considering the well-differentiated phenotype of HELUs,
another apparent paradox was the underexpression of
ITGA6 and ITGB4, which respectively encode α6 and β4
integrin, the two main components of laminin receptor
[40]. However, findings from several immunohistochemical
studies provide a convincing explanation for the down-
regulation of these adhesion molecules. In the normal adult
breast, α6 and β4 integrins are primarily expressed on the
basal surface of myoepithelial cells, where they anchor the
underlying basement membrane, and are weakly expressed
at the basolateral surface of luminal cells [41]. More
detailed studies have shown that cells inside the lobule,
which is not surrounded by a basement membrane, do not
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expression of ITGA6 and ITGB4 that we observed in
HELUs.
Finally, our results are also consistent with a differenti-
ated luminal phenotype in HELUs. We observed underex-
pression of genes encoding growth factors (EGF, MFGE8,
TGFA, and TGFB2) and transcription factors (FOXC1)
that are primarily expressed in normal myoepithelium.
These genes are also overexpressed in basal-like breast
cancers (especially the triple-negative subtype), where they
are involved in cell survival, neoangiogenesis, epithelial-
to-mesenchymal transition, and migration [43-47].
In the gene expression profile for ADHs and DCISs
relative to histologically normal tissue, we found a para-
doxical association between terminal luminal differenti-
ation (indicated by underexpression of basal marker genes
and overexpression of ESR1) and cell proliferation (indi-
cated by overexpression of CCNB1, CCNB2, and MKI67).
The finding is particularly significant in understanding the
neoplastic transformation process because it contradicts
the notion that ER expression and cell proliferation are
two dissociated, if not antithetic, processes in normal lu-
minal cells [48]. Per this dissociation principle, estrogen in-
duces never-dividing, ER-positive cells to produce growth
factors that stimulate proliferation of adjacent, ER-negative
cells in a paracrine manner [49]. Therefore, concomitant
overexpression of ESR1, CCNB1, CCNB2, and MIK67
supports the hypothesis that disrupting the mechanism
governing the dissociation between ER expression and cell
proliferation, and consequently establishing autocrine ER
signaling [50], could be a crucial event in the transition
from ADHs to DCISs, and provides a molecular explan-
ation of why DCISs have a higher risk of progressing
toward invasive cancer. Constitutive expression of ER
allows ADH/DCIS-forming cells to exploit, in an autocrine
manner, the proliferative stimulus induced by estrogens
that bypass the constraint of the ER-proliferation dissoci-
ation, and promotes a dividing, ER-dependent, luminal
phenotype. Notably, ADH/DCIS-forming cells were char-
acterized by overexpression of FOXA1 and GATA3, which
encode two transcription factors (FoxA1 and Gata-3,
respectively) that play a pivotal role in estrogen-regulated
luminal differentiation and ductal elongation [24,51]. In
particular, Gata-3, corecruited with FoxA1 to ER cis-
regulatory elements, is essential for the ER-mediated
transcription of target genes as part of a positive feed-
back loop in which ER expression is required for GATA3
gene transcription [52]. Although FoxA1 and Gata-3 are
recognized pioneer transcription factors, their binding
capability depends on chromatin modifications. Therefore,
the observation that FOXA1 and GATA3 overexpression
was associated with ACTL6A and EZH2 overexpression
was not surprising, as ACTL6A and EZH2 respectively
encode a regulatory component of many ATP-dependentchromatin-remodeling complexes and the inducible cata-
lytic subunit of polycomb repressive complex 2. However,
studies in transgenic mice demonstrated that aberrant
overexpression of EZH2 is associated with disruption of
ductal morphogenesis and promotion of hyperplastic epi-
thelium that is predominantly composed of differentiated
luminal cells expressing ER and high levels of Gata-3 [53].
We observed a dramatic decrease (up to 90% in DCISs
respect to normal tissue) in MME expression in ADHs/
DCISs.MME encodes CD10, a membrane metallopeptidase
prevalently expressed in myoepithelium [54]. In normal
tissue, myoepithelial cells control mammary gland homeo-
stasis by forming a physical barrier between epithelial cells
and the surrounding stroma and secreting paracrine media-
tors that inhibit cell migration [55]. Because the transition
from in situ to invasive carcinoma is associated with the
loss of myoepithelial layer, it is conceivable that the pro-
gressive underexpression of MME we observed in ADHs
and DCISs represents a very early event in the process of
malignant transformation.
When we compared genes that characterize HELUs
with genes that characterize ADHs/DCISs, we found that
HELUs and ADHs/DCISs shared only 5 genes despite
their common luminal origin: EGF, ELF5, FOXC1, JAG2,
and SOX10. Each of these genes was underexpressed
relative to corresponding normal tissue. The underex-
pression of all but ELF5 was expected. In fact, EGF
underexpression is consistent with experimental evidence
that epidermal growth factor supports the development
of bipotent cells into both luminal and myoepithelial
lineages but decreases during luminal lineage differenti-
ation [56]. Similarly, FOXC1 is specifically expressed in the
myoepithelium and overexpressed in ER-negative breast
cancers such as the basal-like type, in which it promotes
the expression of genes involved in the epithelial-to-
mesenchymal transition and enhances the propensity to
metastasize [57]. Interestingly, recent studies have demon-
strated that basal-like breast cancer pathogenesis can be
inhibited by the repressive activity of Gata-3 on FOXC1
expression [58] and by the silencing activity of EZH2
[59]. Our results and the aforementioned results show
that in both types of precursors (HELUs and ADHs/
DCISs), the underexpression of FOXC1 is associated
with the overexpression of GATA3 and EZH2, suggest-
ing that GATA3 and EZH2 protect against the transi-
tion to an invasive mesenchymal phenotype triggered
by FOXC1 overexpression. The underexpression of
JAG2 and SOX10 was also unsurprising, because these
genes, as previously discussed, are involved in promot-
ing and maintaining the stem-like state. Notably, both
genes are specifically expressed in myoepithelial cells
and in breast cancers with a basal phenotype [17,21]. In
regard to ELF5, underexpression interestingly appears
to be progesterone-dependent in HELUs but caused by
Coradini et al. Chinese Journal of Cancer  (2015) 34:3 Page 8 of 9gene promoter methylation in ADHs/DCISs (as sug-
gested by the concomitant overexpression of EZH2).
Conclusions
Although our study has limitations common to the major-
ity of studies involving only gene expression profiling, i.e.,
small number of cases and lack of validation of the
observed mRNA modulations at the protein level, the
results we report here provide interesting information.
Despite their common luminal origin, HELUs and ADHs/
DCISs are distinct entities, characterized by different gene
profiles with very little overlap. In particular, terminal
lobular differentiation of HELUs is characterized by
overexpression of PGR and constitutive expression of
PGRMC1 and PGRMC2 (suggestive of a progesterone-
dependence), whereas the terminal ductal differentiation
of ADHs is characterized by overexpression of ESR1 and
GATA3 (suggestive of an estrogen-dependence) and by
the unexpected concomitant overexpression of CCNB1,
CCNB2, and MKI67. The latter finding is particularly
interesting because it supports early disruption of the
mechanism governing the dissociation between ER expres-
sion and cell proliferation, and the consequent establish-
ment of autocrine ER signaling.
Although clinical evidence indicates that only a small
fraction of HELUs and ADHs evolve to invasive cancer, the
present findings suggest that exposure to synthetic proges-
tins, frequently administered as hormone-replacement ther-
apy, and estrogens, when abnormally produced by adipose
cells and persistently present in the stroma surrounding the
mammary gland, must be regarded as potential causes for
the development of these hyperplastic lesions.
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